CTMedic - Right, that's why maybe the trial analysts and the FDA are taking the time to evaluate the post-28 day mortality rates for both arms. In looking at the chart 5 from the aviptadil trial results, looks like the 28-42 day mortality represents the lion's share of the 28-77 day rate.